Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and match ample to tolerate FCR therapy, may still be superior candidates for that latter, With all the advantage being this treatment method may be completed in six months although ibrutinib should be taken indefinitely. This sel